India to Myanmar: Acetaminophen Export Trade Route

To import finished pharmaceutical formulations containing Acetaminophen into Myanmar, compliance with the National Drug Law (1992) and its subsequent amendments is mandatory. The Myanmar Food and Drug Administration (FDA) oversees the registration and importation of pharmaceutical products.

Registration Process:

1. Application Submission: The importer must submit a registration application to the FDA. As of July 2023, applications are processed through an electronic submission system. The application should include comprehensive information as specified in the Drug Registration Guideline.

2. Dossier Format: The application must be compiled in the ASEAN Common Technical Dossier (ACTD) format, encompassing administrative, quality, non-clinical, and clinical data.

4. Product Samples: The FDA may require submission of product samples for laboratory analysis to verify quality and compliance.

5. Fees: Applicants are subject to registration assessment fees and laboratory analysis fees. As of the latest available information, the registration assessment fee is $100 USD, and the registration fee is $300 USD.

6. Approval Timelines: While specific timelines can vary, the FDA aims to process applications efficiently. Applicants should anticipate a review period that allows for thorough evaluation of the submitted dossier.

Importation Process:

1. Drug Importation Approval Certificate (DIAC): Upon successful registration, the importer must obtain a DIAC from the FDA before importing the product.

2. Import License: With the DIAC, the importer applies for an import license from the Department of Trade, Ministry of Commerce.

3. Compliance with Import Procedures: The importer must adhere to the import procedures outlined by the Ministry of Commerce, including obtaining import price confirmation from the Myanmar Pharmaceutical & Medical Equipment Entrepreneurs' Association (MPMEEA).

GMP Inspection Requirements:

The FDA may conduct GMP inspections of foreign manufacturing facilities to ensure compliance with Myanmar's quality standards. Manufacturers should be prepared for such inspections and maintain up-to-date GMP certification.

Indian exporters of Acetaminophen formulations must adhere to stringent quality and GMP standards to supply products to Myanmar.

GMP Certification Requirements:

1. Valid GMP Certification: Manufacturing facilities must possess a valid GMP certificate issued by the competent authority in India, such as the Central Drugs Standard Control Organization (CDSCO).

2. Compliance with International Standards: Facilities should comply with international GMP standards, such as those outlined by the World Health Organization (WHO).

Approved Indian Facilities:

Specific information regarding Indian manufacturing facilities currently approved by the Myanmar FDA is not publicly disclosed. Exporters should ensure their facilities meet all regulatory requirements and maintain open communication with the FDA for approval status.

Recent Inspections and Regulatory Actions:

As of March 2026, there have been no publicly reported inspections or regulatory actions by the Myanmar FDA against Indian pharmaceutical companies. However, exporters should remain vigilant and ensure continuous compliance with all regulatory standards to avoid potential actions.

Several regulatory changes have occurred in Myanmar between 2024 and 2026, impacting the importation of pharmaceutical products:

Exporters and importers should stay informed about these regulatory developments to ensure compliance and facilitate the smooth importation of pharmaceutical products into Myanmar.

In 2025, Myanmar's analgesics market, which includes acetaminophen formulations, is projected to reach approximately $63.75 million, with an anticipated annual growth rate of 1.70% from 2025 to 2030. This growth is driven by increasing healthcare expenditures, a rising prevalence of pain-related ailments, and a growing preference for over-the-counter pain relief medications. While specific data on domestic production versus imports of acetaminophen formulations is limited, the market's expansion suggests a reliance on both imported and locally manufactured products to meet the rising demand.

Myanmar imposes a Most-Favored-Nation (MFN) import duty rate of 5% on pharmaceutical products classified under HS code 30049069, which includes finished dosage forms containing acetaminophen. Additionally, imports are subject to a commercial tax, which functions similarly to a value-added tax (VAT), typically ranging from 5% to 15%, depending on the product category. Myanmar is a member of the Regional Comprehensive Economic Partnership (RCEP), which aims to reduce tariffs among member countries over time. However, specific tariff reductions for pharmaceutical products under RCEP are subject to the agreement's implementation schedule and may not yet be in effect. There are no publicly documented anti-dumping duties specifically targeting pharmaceutical imports from India into Myanmar.

India is a significant supplier of acetaminophen formulations to Myanmar, accounting for approximately 0.7% of India's total exports of these products, valued at $1.6 million across 15 shipments from nine Indian manufacturers. The primary exporter is Lincoln Pharmaceuticals Ltd., contributing $1.5 million to this trade. The main importer in Myanmar is Universal Co. Ltd., with imports totaling $1.5 million. While India plays a crucial role in supplying acetaminophen formulations to Myanmar, other countries, including China and various European Union member states, also export these products to the Myanmar market. Specific data on India's share relative to other suppliers and comparative pricing information is not readily available. However, India's pharmaceutical industry is known for its cost-effective production capabilities, which may offer competitive pricing advantages over manufacturers from higher-cost regions.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of the global generics trade by volume as of 2025. The country's pharmaceutical manufacturing sector boasts an annual capacity exceeding 70 billion dosage units, encompassing a wide range of finished dosage forms, including tablets, capsules, syrups, and injections. (zipdo.co)

The cost structure of Indian pharmaceutical manufacturing is notably competitive, with production costs estimated to be 30-35% lower than those in the United States and Europe. This advantage is primarily due to lower labor costs, stringent cost-control measures, and the accelerated adoption of digital technologies.

India's commitment to quality is evident in its substantial number of regulatory approvals. As of 2024, the country operates 752 FDA-approved generic medicine facilities, surpassing the United States, and 2,050 WHO-GMP certified facilities. These facilities are regularly inspected and adhere to the highest global standards, ensuring the production of safe and effective medicines.

In the global market for Acetaminophen formulations, India offers a compelling balance of cost-effectiveness and quality. In Q2 2025, the price of Paracetamol (Acetaminophen) in India was approximately USD 2,958 per metric ton, significantly lower than in the USA (USD 3,821/MT), China (USD 3,732/MT), Germany (USD 3,767/MT), and France (USD 3,965/MT).

Quality perception and regulatory acceptance are critical factors in pharmaceutical procurement. India's pharmaceutical industry has made substantial investments in infrastructure and operations to meet global regulatory standards. Between 2013 and 2024, the number of "Official Action Indicated" (OAI) notices issued by the FDA to Indian firms dropped by 50%, reflecting significant improvements in compliance outcomes.

Supply reliability is another crucial consideration. India's pharmaceutical industry has demonstrated a strong track record in maintaining consistent supply chains, supported by its extensive manufacturing capacity and adherence to international quality standards.

The India-Myanmar supply chain for Acetaminophen formulations has proven to be reliable, underpinned by India's substantial manufacturing capacity and stringent quality controls. The country's pharmaceutical sector operates over 70 billion dosage units annually, ensuring the ability to meet both domestic and international demand. (zipdo.co)

Packaging and cold chain capabilities are integral to maintaining the integrity of pharmaceutical products. Indian manufacturers have invested in advanced packaging technologies and cold chain logistics to ensure product stability during transit, aligning with international standards.

Regulatory compliance is a cornerstone of India's pharmaceutical industry. The significant reduction in FDA OAI outcomes over the past decade underscores the industry's commitment to maintaining high compliance standards.

Regarding capacity constraints or expansion plans, leading Indian pharmaceutical companies have been investing in infrastructure and operations to meet global demand. For instance, Glenmark Pharmaceuticals received FDA approval for Acetaminophen and Ibuprofen Tablets in April 2024, indicating ongoing expansion in production capabilities.

For Myanmar buyers sourcing Acetaminophen formulations from India, the following strategic recommendations are advised:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers. Establish clear communication with potential suppliers to understand their specific requirements and negotiate terms that align with your procurement needs.

• Payment Terms: Common payment terms in India-Myanmar pharmaceutical trade include Letters of Credit (LC) and advance payments. It's essential to negotiate terms that balance financial security and cash flow considerations.

• Supplier Qualification Process: Implement a rigorous supplier qualification process, including audits of manufacturing facilities, verification of regulatory certifications (such as WHO-GMP and FDA approvals), and assessment of quality control systems.

• Regulatory Compliance: Ensure that the selected suppliers comply with both Indian and Myanmar regulatory requirements. This includes adherence to import regulations, product registration, and labeling standards.

By adhering to these recommendations, Myanmar buyers can establish a robust and reliable supply chain for Acetaminophen formulations sourced from India.

By adhering to this comprehensive approach, Myanmar companies can ensure the selection of reliable Indian suppliers for Acetaminophen formulations, safeguarding product quality and regulatory compliance.